EMERALD Subgroup Analysis in HER2-Low Metastatic Breast Cancer: Safety and Efficacy of Elacestrant

Opinion
Video

A comprehensive review of the safety and efficacy from a HER2-low subgroup analysis in the EMERALD Trial presented at SABCS 2023 and clinical implications in practice.

Recent Videos
1 KOL is featured in this series.
Hope S. Rugo, MD, FASCO, is featured in this series.
Hope S. Rugo, MD, FASCO, is featured in this series.
Hope S. Rugo, MD, FASCO, is featured in this series.
Hope S. Rugo, MD, FASCO, is featured in this series.
Related Content